| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TaiMed Biologics Inc (TWO: 4147)
4147 Technical Analysis
1
| As on 9th Jun 2023 4147 STOCK Price closed @ 105.50 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS. |
4147STOCK Price
| Open | 107.50 | Change | Price | % |
| High | 108.50 | 1 Day | N/A | N/A |
| Low | 105.00 | 1 Week | 0.00 | 0.00 |
| Close | 105.50 | 1 Month | 0.00 | 0.00 |
| Volume | 1359028 | 1 Year | 0.00 | 0.00 |
| 52 Week High 0.00 | 52 Week Low 0.00 | ||||
TWO Taiwan Most Active Stocks
| 6125 | 44.70 | % |
| 4533 | 18.00 | % |
| 4979 | 76.40 | % |
| 6122 | 44.45 | % |
| 5425 | 102.00 | % |
| 8358 | 63.30 | % |
| 3374 | 128.00 | % |
| 2743 | 162.50 | % |
| 8069 | 227.00 | % |
| 1815 | 13.95 | % |
TWO Taiwan Top Losers Stocks
| 3652 | 22.55 | -0.88% |
| 4147 Daily Charts |
4147 Intraday Charts |
Whats New @ Bazaartrend |
4147 Free Analysis |
|
|
4147 Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
4147 Forecast September 2023
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
4147 Weekly Forecast
| 4th UP Forecast | 0.00 |
| 3rd UP Forecast | 0.00 |
| 2nd UP Forecast | 0.00 |
| 1st UP Forecast | 0.00 |
| 1st DOWN Forecast | 0.00 |
| 2nd DOWN Forecast | 0.00 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | 0.00 |
4147 Forecast2023
| 4th UP Forecast | 0 |
| 3rd UP Forecast | 0 |
| 2nd UP Forecast | 0 |
| 1st UP Forecast | 0 |
| 1st DOWN Forecast | 0 |
| 2nd DOWN Forecast | 0 |
| 3rd DOWN Forecast | 0 |
| 4th DOWN Forecast | 0 |
TaiMed Biologics Inc ( TWO Taiwan Symbol : 4147 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
4147 Business Profile
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody that is in Phase II clinical trials for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase II clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which is in Phase I clinical trials for treating HIV infections; TMB-370, a bispecific neutralizing antibody that is in Phase I clinical trials to treat HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was founded in 2007 and is headquartered in Taipei, Taiwan. Address: No. 607, Ruiguang Road, Taipei, Taiwan, 11492
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service